Emerging evidence suggests that ISG15, a protein involved in post-translational modifications, stabilizes ATG7 structure and function while augmenting autophagic flux to counteract gemcitabine (GEM) sensitivity in pancreatic cancer (PC) therapy—a factor associated with poor prognosis in PC (60). The gene discussed is ISG15; the disease is pachyonychia congenita.